TMPRSS2-ERG fusion can block XRCC4-mediated NHEJ by inhibiting DNA-PKcs auto/trans-phosphorylation and thus sensitizes prostate cancer cells to PARP inhibition [86]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.